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Cachexia, a syndrome characterized by weight loss, anorexia,
weakness and asthenia, may be seen in up to 80% of patients with
gastrointestinal cancers (Bruera, 1997). Cachexia and weight loss
are associated with impaired quality of life and reduced survival in
patients with advanced cancer (Dewys et al, 1980). 
Proteolysis-inducing factor (PIF) was identified as a tumour
product in the circulation of mice bearing a cachexia-inducing
tumour but not in mice bearing a tumour that does not induce
cachexia (Todorov et al, 1996b). PIF, a glycoprotein of relative
molecular mass 24 kDa, caused weight loss by inducing enhanced
protein degradation without decreasing the appetite in mice. PIF
was also found to be present in the urine of cachectic cancer
patients while being absent from normal subjects, individuals 
with weight loss due to trauma and cancer patients with little or no
weight loss (Todorov et al, 1996a). However, human tumours 
have not been shown to express PIF, and tumour expression of 
PIF has not been correlated with weight loss in humans. This study
was conducted to examine these important issues linking PIF to
cachexia in humans. 
MATERIALS AND METHODS 
Patients 
We studied 16 tumour samples from patients with gastrointestinal
cancers who had undergone surgery or biopsy at the Lombardi
Cancer Center, Georgetown University Medical Center. The
samples consisted of formalin-fixed, paraffin-embedded tissue, of
which 4–5 mm sections were obtained for analysis. For most
patients, only tumours from metastatic sites were available. Medical
records were reviewed to determine the type and stage of cancer at
the time of diagnosis, and to obtain serial weight measurements. 
Urine samples 
5 ml aliquots of urine were collected from all patients on the study.
The samples were concentrated (50x), dialysed (cut off 18 kDa) at
4˚C using Minicon B15 concentrator (Millipore Corp, Burlington,
MA) to remove low-molecular mass species, and further diluted in
water for analysis. 
Immunohistochemistry 
Tissue sections were deparaffinized, hydrated, and heated in a
citrate buffer (10 mM, pH 6.0) at 90˚C for 30 min. Nonspecific
reactivity was blocked by incubation with 10% normal horse
serum for 30 minutes, followed by addition of the anti-PIF anti-
bodies (generously provided by Dr Michael Tisdale, Aston
University, Birmingham, UK) at a concentration of 25 mg ml–1.
The tissue sections were incubated overnight at 4˚C. After
multiple PBS washes, tissue sections were incubated for 20 min at
room temperature with biotinylated anti-mouse IgG antibody
made in goat. The detection system was Avidin–Biotin Complex
(ABC, Vector Labs Inc, Burlingame, CA) which was incubated
with the tissue for 30 min at 37˚C. After multiple washes, peroxide
activity was visualized after reaction with diaminobenzamine
followed by nuclear counter staining with haematoxylin, dehydra-
tion in ETOH gradients, xylene and finally mounting under cover-
slips. The negative controls were tissue without primary antibody,
an irrelevant negative antibody and a mouse IgG2a, kappa (UPC
10) purified immunoglobulin at the same concentration as anti-PIF
antibody. All tissue sections were evaluated for PIF expression by
2 investigators. Tumour, epithelial and mesenchymal cells, and
the extracellular matrix were evaluated for PIF staining. The
percentage of stained cell were taken as a measure of PIF expres-
sion. Tissue was considered positive for PIF expression if a granular
staining pattern was found in the cytoplasm of more than 30%
cells at a magnification of 1003
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Urine samples were analysed by capillary electrophoresis, and
structural assignments were made by Western blot analyses using
antibodies raised against murine PIF and cross validated with
off-line matrix assisted laser desorption ionization time of flight
(MALDI TOF) mass spectrometry as previously described
(Choudhary et al, 1999). Briefly, the separation was performed on
a 64.5 cm ´ 75 mm ID fused-silica capillary column at an applied
voltage of 15 kV with 60 mM sodium tetraborate, pH 9.2 as the
buffering electrolyte. The peak eluting at 15 min could be identi-
fied as PIF. Micropreparative CE was performed and the fraction
containing the factor was collected for off-line analysis by
MALDI-TOF. Typically, 50–100 laser shots were summed for
each spectrum. Mass calibration was performed using a protein
standard (G-2053A, Hewlett Packard) comprising myoglobin,
cytochrome C and bovine serum albumin. 
RESULTS 
PIF staining was detectable in the tissue from 6 patients (2 colon, 
1 pancreatic, 2 gastric, 1 cholangio-carcinoma) and appeared as
granular cytoplasmic staining within cells. The staining was
observed in the cytoplasm of tumour cells in 5 patients, and in the
cytoplasm of epithelial and mesenchymal cells surrounding the
tumour in 1 patient. The number of stained cells in tumours var-
ied from 30% to 80% positive cells. Staining was seen in clusters
of tumour cells as well as single malignant cells scattered in
the parenchyma. Moderate to poorly differentiated carcinomas
showed stronger staining compared with well-differentiated carci-
nomas. Representative positive and negative results for tumour
cells are shown in Figure 1(A). The single case of non-tumoral
staining was observed in approximately 60% of mucosal and
periglandular cells in a patient with gastric carcinoma (Figure 1C).
Tumour cells in this case showed faint staining for PIF in < 20% of
cells (data not shown). The 2 investigators had < 8% discrepancy
between estimates of the number of stained cells in tissue sections. 
Urine for PIF was collected at varying time intervals following
diagnosis. All patients with positive staining for PIF in their tissue
samples had detectable PIF in the urine as shown in Table 1. PIF
was detectable as a ~24 kD protein eluting at 15 minutes, and was
identified using Western blot analysis employing antibodies raised
against PIF isolated from a murine adenocarcinoma, MAC-16. PIF
was detectable in urine up to 2 years following diagnosis in
patients who had positive staining in the tissue biopsy. A variety of
gastrointestinal carcinomas were studied, and the site of the
primary tumour had no effect on the presence of PIF. The detection
of PIF in tissue and urine was also not dependent upon the pres-
ence of secondary metastatic tumours. 
There was strong correlation between the presence of PIF in
tumour and urine, and weight loss. All 6 patients whose tissues
and urine tested positive for PIF had experienced weight loss
between 8% and 39% of the pre-illness weight (average 18%),
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Figure 1 (A) Colorectal carcinoma showing expression of PIF in the cytoplasm of tumour (immunohistochemistry, x400). (B) Negative control. (C) Gastric
glands showing expression of PIF in glandular epithelial and periglandular cells (Immunohistochemistry, x400). (D) Negative control. while 8 patients whose tissues and urine tested negative for PIF
had experienced weight loss of between 1% and 7% (average 5%).
2 remaining patients who had also tested negative for PIF in tissue
and urine samples, had experienced weight loss that was attributed
to concomitant medical problems that impaired food intake
(weight loss of 15% and 22% of the pre-illness weight, attributed
to biliary obstruction and intestinal obstruction, respectively). 
DISCUSSION 
The identification of proteolysis-inducing factor (PIF) in the urine
of cachectic patients, and correlation of its presence with weight
loss have helped establish PIF as a novel cachectic factor in
humans (Todorov et al, 1996a; Wigmore et al, 2000). However,
these studies have been criticised because the authors identified
PIF only in the urine and not in the serum (Gullu and Marangoz,
1999). Moreover, the source of PIF in cachectic patients was
unknown. It was thought that human tumours, like mouse tumours,
produce PIF but direct evidence of PIF expression in tumours was
lacking. Our data show that PIF is expressed in tumours and
mesenchymal tissue of patients who have PIF detectable in the
urine, and is strongly associated with weight loss in cancer
patients. The low abundance of PIF in serum (about 40 ppb) would
require extensive prepurification for detection of the factor, and
has been the primary obstacle in using serum measurements for
studies (Tisdale, 1999). While we did not measure PIF in serum,
the detection of PIF in tumours and urine of the same patients
implies its transport through the bloodstream. 
While PIF was expressed predominantly in tumour tissue,
it was interesting to note that one tumour biopsy showed PIF
expression in mucosal and periglandular cells situated close to the
tumour. This could suggest several possibilities: PIF may be an
inducible factor, and may be expressed in surrounding epithelial
and mesenchymal cells under the influence of tumour cells.
Alternatively, PIF could be a secreted factor that is stored in
the cells surrounding the tumour. Further studies will be needed
to confirm this observation and to identify the mechanisms of
production and secretion of PIF. 
In conclusion, data from our study show that tumours are the
source of PIF in patients with gastrointestinal cancers, and the
expression of PIF in tumours correlates directly with its presence
in urine. These data are also consistent with prior studies corre-
lating the presence of PIF in the urine with weight loss in cancer
patients. We are prospectively evaluating tumour, serum and urine
PIF as a markers of cachexia and disease prognosis in patients with
gastrointestinal cancers. 
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Table 1 Comparison PIF expression in tumour tissue and urine, and comparison with weight loss in patients with gastrointestinal carcinomas 
Patient No. Primary tumour Tissue PIF staining  Urine PIF Weight loss (%) 
Date Biopsy site Result Date of collection Result 
1 Colon 4/98 Colon (–) 4/98 (–) 7 
2 Colon 2/97 Liver (–) 2/99 (–) 4 
3 Colon 7/97 Colon (+) 2/98 (+) 9 
4 Colon 7/96 Lung (+) 12/97 (+) 24 
5 Pancreas 7/98 Lymph Node (–)  7/98 (–) 4 
6 Pancreas 3/97 Liver (–) 3/98 (–) 15* 
7 Pancreas 2/98 Ascitic Fluid Cells (–) 9/98 (–) 6 
8 Pancreas 6/98 Pancreas (+) 6/98 (+) 8 
9 Gastric 7/97 Peritoneal Deposit (–) 7/97 (–) 3 
10 Gastric 10/96 Esophagus (–) 3/98 (–) 5 
11 Gastric 3/98 Esophagus (–) 3/98 (–) 6 
12 Gastric 9/98 Esophagus (–) 9/98 (–) 1 
13 Gastric 11/98 Liver (+) 11/98 (+) 14 
14 Gastric 4/98 Esophagus (+) 4/98 (+) 39 
15 Small Bowel 1/98 Abdominal Wall (–) 1/98 (–) 22** 
16 Cholangio-carcinoma 12/98 Liver (+) 12/98 (+) 18 
* Biliary obstruction, ** intestinal obstruction. 